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ABSTRACT
Objective: To determine whether the activation of innate immune responses, which can be elicited
by pathogenic and endogenous triggers, is associated with the presence of Epstein-Barr virus
(EBV) infection in the multiple sclerosis (MS) brain.
Methods:White matter postmortem MS (n 10) and control tissue (n 11) was analyzed for the
expression of the proinflammatory cytokine interferon  (IFN) by immunohistochemistry and for
EBV by using the highly sensitive method of EBV-encoded RNA (EBER) in situ hybridization.
Results:We detected overexpression of IFN in active areas of white matter MS lesions but not in
inactive MS lesions, normal-appearing white matter, or normal brains. The presence of IFN in
macrophages and microglia (expressing human leukocyte antigen class II) is suggestive of local
production as part of an acute inflammatory process. Interestingly, EBERs were also specifically
detected in areas where IFNwas overexpressed in these preselected active MS lesions. EBER
cells were also found in CNS lymphoma and stroke cases, but were absent in other control brains.
We next addressed a potential mechanism, e.g., the role of EBERs in eliciting IFN production,
and transfected EBERs into human embryonic kidney (HEK) cells. We used HEK cells that stably
expressed Toll-like receptor-3, which recognizes double-stranded RNAs, associated with many
viral infections. EBERs elicited IFN production in vitro.
Conclusion: These findings suggest that latent EBV infection may contribute to the inflammatory
milieu in active MS lesions by activating innate immune responses, e.g., IFN production. Unrav-
eling the underlying mechanisms may help in uncovering causal pathways and developing better
treatment strategies for MS and other neuroinflammatory diseases. Neurology® 2012;78:15–23
GLOSSARY
ds double-stranded;EBEREBV-encoded RNA;EBNA-1EBV nuclear antigen 1;EBVEpstein-Barr virus; FCS fetal
calf serum; H&E  hematoxylin & eosin; HEK  human embryonic kidney; HLA  human leukocyte antigen; HSE  herpes
simplex encephalitis; IFN interferon ; IgG immunoglobulin G; ISH in situ hybridization; LFB Luxol fast blue;mAb
monoclonal antibody; MS  multiple sclerosis; OHL  oral hairy leukoplakia; PBS  phosphate-buffered saline; pDC  plas-
macytoid dendritic cell; PLP  protein lipid protein; SLE  systemic lupus erythematosus; SSPE  subacute sclerosing
panencephalitis; TLR3 Toll-like receptor-3.
The innate immune response is an essential part of the host response to many infections and
type I interferon (IFN) is produced within hours of systemic infection.1 Our previous findings
showed that Toll-like receptor-3 (TLR3) stimulation of human microglia with the viral-mimic
polyIC led to IFN production and downstream Th1 polarization of CD4 helper T cells,2
which may impact on CNS immunity.
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Infectious agents are plausible candidates
for triggering and perpetuating multiple scle-
rosis (MS) in genetically susceptible subjects.
The strength of its associations renders
Epstein-Barr virus (EBV), a herpesvirus with
a population prevalence90%, the outstand-
ing candidate. A history of symptomatic in-
fectious mononucleosis increases the MS risk
more than twofold3 and elevated serum anti-
body titers to EBV nuclear antigen 1
(EBNA-1) precede the onset of MS, and are
associated with MRI activity in established
disease.4,5 Furthermore, EBV infection was
found to be a characteristic feature of the MS
brain6; however, these findings were coun-
tered by other studies.7–9
EBV infects predominantly B lymphocytes
and persists in the blood in rare memory B
cells. The gold standard for detecting EBV in
tissue is in situ hybridization for the EBERs, 2
small EBV-RNAs (EBER1 and EBER2),
abundant in EBV-infected cells (106–107
copies/infected cell nucleus)10 with immuno-
modulatory effects upon secretion and TLR3
ligation on neighboring cells.11
Our hypothesis is that active MS lesions
carry an IFN signature, which can be elic-
ited by viral stimuli. We propose that innate
activation in these areas, driven or maintained
by EBV-encoded RNAs, leads to an antiviral
state that contributes to neuroinflammation.
METHODS Standard protocol approvals, registra-
tion, and patient consents. Postmortem paraffin brain and
control tissues were obtained from the Thomas-Willis-Oxford
Brain Collection, Oxford, with informed consent and Ethics
Committee approval (REC: 08/H0304/7).
Tissue specimens. For all MS brains studied, the clinical diag-
nosis had been made during life and confirmed at autopsy. Brains
from patients with cancer and other neurologic and neuroinflam-
matory diseases were used as controls (table e-1 on the Neurology®
Web site at www.neurology.org). To characterize white matter le-
sions, Luxol fast blue (LFB), anti–human leukocyte antigen (HLA)
class II (macrophages/microglia), and hematoxylin & eosin (H&E)
staining was performed to identify the centers and borders of lesions
and their activity, and areas of hypercellularity (inflammatory cell
infiltration) and hypocellularity (loss of parenchymal cells in inac-
tive lesions). Lesions were classified into 3 groups: 1) acute lesions,
rich in dense lymphocytic infiltrates with numerous B cells and
macrophages (containing LFB); 2) chronic active lesions, character-
ized by hypercellular active borders staining strongly for LFB in
macrophages and hypocellular demyelinated centers, with very low
densities of LFB-negative macrophages; 3) inactive lesions, charac-
terized by demyelination and marked hypocellularity (reflecting loss
of parenchymal cells) and only limited numbers of LFB-negative
inflammatory cells. Case 13 is a stroke case with cause of death
noted as cerebral hemorrhage with some B-cell infiltration, whereas
case 12, without B-cell infiltration, died of pulmonary embolism.
Immunohistochemistry for IFN, gp350, LMP-1, and
plasmacytoid-dendritic-cell markers. Paraffin sections (6
m) used in this study were deparaffinized and antigens un-
masked as described previously.12 Sections were blocked with
10% fetal calf serum (FCS) followed by staining with sheep
polyclonal anti-IFN antibody at 1/1,000 dilution in 10% FCS.
This antibody was raised against lymphoblastoid IFN and is
thus broadly cross-reactive with IFN subtypes.13 Antisheep im-
munoglobulin G (IgG) antibody (Vector, UK) was used as sec-
ondary antibody followed by avidin-biotin peroxidase complex
(ABC kit, Vector, UK) and detected with diaminobenzidine
substrate (DAKO, UK). B cells in MS lesions were stained with
anti-CD79, which is part of the B cell receptor complex
(JCB117 clone, donated by Prof. Margaret Jones),14 and devel-
oped with Dako Real Envision Detection System as described
previously.12 LMP-1 and gp350/220 were detected with the
mouse IgG1 monoclonal antibodies (mAb) OT21C (LMP-1;
1/500) and OT6 (gp350; 1/2,000), both of mouse origin
(IgG1), in phosphate-buffered saline (PBS) containing 1% bo-
vine serum albumin.15 Binding was visualized with labeled poly-
mer HRP (peroxidase-labeled polymer conjugated to goat
antimouse and goat antirabbit Igs in Tris-HCl buffer, Dako,
UK) for 30 minutes followed by DAB as above. All sections were
counterstained with hematoxylin. pDCs staining was done as
described previously using BDCA2 clone 124B3.13 (1/50)
(Dendritics, France)16,17; CD2ap, clone B-4 (1/1,000; Santa
Cruz Biotechnology, USA)18; and CD123, clone 7G3 (1/50; BD
Biosciences, USA).
Immunofluorescence staining. For double-labeling, IFN
staining was performed as described above, followed by biotin-
antisheep Ig (Vector, UK), visualized with conjugated streptavi-
din alexa-488 (Invitrogen, Paisley, UK). Slides were incubated
overnight with second primary antibodies: rat anti–major histo-
compatibility complex class II (1/200 dilution; Dako, UK), rat
anti-CD3 (1/100; Serotec UK), mouse anti-CD19 (1/50; Sero-
tec, UK), rabbit anti-GFAP (1/1,000; Dako, UK), or mouse
anti–protein lipid protein (PLP) (1/200; Serotec). Appropriate
secondary antibodies included Alexa 568 anti-rat Ig (1/200; In-
vitrogen, UK), Alexa 568 antimouse Ig (1/200), and Alexa Fluor
568-antirabbit (1/200) for 3 hours. As negative controls for each
second layer, primary antibodies were omitted. No staining was
seen in these sections.
In situ hybridization for the detection of EBERs in
brain tissue. The EBER–in situ hybridization (ISH) was car-
ried out essentially as previously described in detail.10,19 Two an-
tisense oligonucleotides (30 nucleotides each) corresponding to
positions 91–120 and 82–111 of EBER 1 and EBER 2, respec-
tively, were synthesized (Sigma, UK) and end-labeled by tailing
with digoxigenin-dUTP using a commercially available kit
(Roche Diagnostics, UK), following the manufacturer’s instruc-
tions. Briefly, 6-m sections on sialinized slides were dewaxed
and digested with 100 g/mL proteinase K for 15 minutes in a
37°C incubator. Sections were subsequently washed in water and
dehydrated in ethanol. Sections were incubated with hybridiza-
tion buffer containing 100 ng/mL of EBER-1/EBER-2 probe.
The EBER probes and target nucleic acid were denatured using
microwave irradiation followed by hybridization overnight at
42°C in a hot air oven. After high-stringency washes in
0.1 SSC at 55°C, hybridized probes were detected using mouse
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antidigoxin mAb (1/5,000; Sigma, UK) followed by the avidin-
biotin complex peroxidase technique (ABC-Elite kit, Vector
Laboratories, UK) and DAB as the chromogenic substrate. We
examined all lesions blindly, i.e., without knowledge of the other
results or the histologic status of the MS lesions. A negative con-
trol (using PBS instead of EBER probes) was included with each
sample. Hodgkin lymphoma or post-transplant lymphoma
(PTLD) sections were included as positive controls with each
batch. In our previous studies,10,19 negative controls included
treatment of sections with RNase prior to hybridization with
EBER probes and using random probes of the same size and GC
content to EBER probes. Our findings consistently showed that
our EBER probes were highly specific, giving positive signals
only in samples containing EBV.
EBER-encoding plasmids. Plasmids encoding EBER1
or EBER2 were prepared by cloning PCR-amplified B95–8
EBV EBER1 or EBER2 DNA digested with BglII and HindIII
into pSUPER (OligoEngine Ltd., Seattle) between the BglII and
HindIII sites. EBER plasmids were calibrated and found to give
transient expression similar to that found in EBV-infected cells
as determined by Northern blotting and flow cytometric staining
for EBER-RNA.
Primers were as follows:
EBER1Bgl II CCAGATCTCCAGGACCTACGCTGCCCT
EBER1Hind III CCAAGCTTGGATGCATAAATCCTAA
EBER 2Bgl II CCAGATCTCCAGGACAGCCGTTGCCCT
EBER 2Hind III CCAAGCTTGGGTGCAAAACTAGCCA
Transfection of EBER-encoding plasmids into
HEK293/TLR3 cells. HEK293 cells stably transfected with
TLR3 (Invivogen, UK) were cultured in Dulbecco modified Ea-
gle medium supplemented with 10% FCS, penicillin (100
U/mL), and streptomycin (100 g/mL) and 5 g/mL of blasti-
cidin for selection.
Plasmids encoding EBER1, EBER2, or empty vector were
used to transfect HEK293/TLR3 cells, seeded at 7.5  104/mL
in 24-well plates. Cells were 80% confluent at the time of trans-
fection with Fugene HD (Roche) at a ratio of 0.75 g Fugene:
0.5 g of DNA. A GFP-encoding plasmid (Lonza, UK) was
cotransfected as a control and comparable transfection efficiency
checked by microscopy. As positive controls, cells were transfected
with polyIC at the same ratio. Transfections were performed in
duplicate and supernatants were collected after 24 hours of culture;
their IFN content was determined with a human IFN multi-
subtype ELISA kit (PBL Interferon Source, UK).
Data acquisition and statistical analysis. The numbers of
IFN cells/mm2 were counted in 3 100 parenchymal fields
per lesion with a total area  1.735  106 m2 using ImageJ
(NIH). Digital images of tissue sections were made with Olym-
pus light microscope BX41 and Zeiss camera (Zeiss, Thorn-
wood, NY). To investigate IFN protein colocalization,
multiple images were acquired using a confocal microscope (Bio-
Rad, Hercules, CA). We performed semiquantification by
counting of EBER, LMP-1, and gp350 cells in perivascu-
lar cuffs and parenchyma of MS lesions with different activity
and observations were confirmed blindly by a second patholo-
gist. Statistical analysis was performed using analysis of variance
(SPSS, IBM).
RESULTS IFN is expressed in active areas of MS
lesions by HLA class II– expressing cells. To investi-
gate the potential role of innate immunity in the
pathogenesis of MS, we studied the expression of
IFN within white matter of MS lesions with differ-
ent disease activity. Large numbers of cells labeling
very strongly for IFN were observed consistently
in all the acute lesions (figure 1A) and borders of
chronic active MS lesions (figure 1B). In contrast, we
found 5 times fewer IFN cells in the inactive
centers of chronic active MS lesions (figure 1C) and
in inactive MS lesions (figure 1D). IFN cells were
rare in normal-appearing white matter (figure 1E)
and normal control brain tissue (figure 1F). These
differences and their significance are quantified in
figure 1J.
The IFN-producing cells were consistently HLA
class II in MS lesions, and showed the morphology
of macrophages/microglia (figure 1, G–I). In sharp
contrast, B cells (CD19), T cells (CD3), astro-
cytes (GFAP), and oligodendrocytes (PLP)
showed no detectable immunoreactivity for IFN
(figure e-1A).
Detection of EBV RNAs and proteins in active MS
lesions that show IFN signatures. We next checked
for the presence of EBV-infected cells in active MS
lesions overexpressing IFN by EBER-ISH. This ap-
proach, therefore, represents a preselection strategy
to identify active MS lesions, and increase the possi-
bility of finding EBER cells. Positive controls
included Hodgkin–, post-transplant–, and AIDS–
associated CNS lymphomas and oral hairy leukopla-
kia (OHL), all of which were known to be EBV.
Our disease controls were 2 cases of stroke and 1 each
with subacute sclerosing panencephalitis (SSPE) and
herpes simplex encephalitis (HSE), and there were 2
healthy control brains (table e-1).
We observed EBER cells in white matter areas
of all the active MS lesions (figure 2A), including
active areas of chronic-active MS lesions (figure 4A
and figure e-2, C). In all cases, the EBER signal was
nuclear, as in the Hodgkin lymphoma control (figure
2D). We semiquantified EBER cells in perivascu-
lar cuffs and categorized cases into () no EBER
cells; () 1–5 EBER cells; () 6–20 EBER
cells; () more than 20 EBER cells; and
() more than 20 EBER cells in perivascu-
lar cuffs and additional dispersed positive cells in pa-
renchyma as shown in table e-1. The perivascular
areas of most active MS cases harbored around 20
EBER cells.
We next checked for EBV-encoded markers for
its latency program II/III (LMP-1) and lytic replica-
tion (gp350). The LMP-1 antibody stained cyto-
plasm and surface membranes in the Hodgkin
lymphoma (figure 2E) as previously described.20 We
observed cross-reactivity of LMP-1 with -synuclein
in brain tissue, which led to strong background stain-
ing, particularly in the cortex rather than white
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Figure 1 Interferon  (IFN) is expressed in white matter areas of active multiple sclerosis (MS) lesions by
human leukocyte antigen (HLA) class II cells
(A–F) IFN immunostaining (brown signal) in MS lesions of different activity. (A) Acute lesion (case 1). In (B), an active border
of a chronic active lesion is seen (case 6A) and in (C), an inactive center of a chronic active lesion (case 6A). (D) Inactive
lesion (case 6B), (E) normal-appearing white matter (NAWM) (case 3), and (F) control brain tissue (case 8). All sections were
counterstained with hematoxylin. Scale bar 50 m. In (G), staining of active area of chronic active lesion (case 5) for IFN
(green), and in (H) for major histocompatibility complex (MHC) class II (macrophages/microglia; red). (I) Overlay of IFN and
MHC class II staining (yellow). Scale bar: 10 m. (J) Histogram shows quantitative analysis of density of IFN cells in MS
lesions of different activity, in NAWM and in control brain (cases 1–9). Significantly higher densities of IFN cells were
present in acuteMS lesions (1309.4 cells/mm2) and active borders of chronic activeMS lesions (114.89.7 cells/mm2)
compared to inactive MS lesions (18.22  2.8 cells/mm2), NAWM (4.4  1.2 cells/mm2), and control tissue (12.25  2.0
cells/mm2), p 0.0001.
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matter areas.21 We detected gp350 cells in OHL
tissue (figure 2F). We only found the occasional
LMP-1 and gp350 cell in EBER active MS
lesions (figure 2, B and C). The results of this semi-
quantification are shown in table e-1. We also
stained consecutive sections for EBERs and IFN.
Indeed, areas of acute MS lesions consistently exhib-
ited a dual IFN/EBER signature (figure 3, A and
B). EBER and IFN cells were found in perivas-
cular areas, however, IFN cells were also promi-
Figure 2 Epstein-Barr virus (EBV) infection is found in active multiple sclerosis (MS) lesions by in situ hybridization
and immunohistochemistry
(A, D) Expression of EBV-encoded RNA (EBER) (EBER1/EBER2, brown signal) in active MS lesion (A: case 4B) and Hodgkin lymphoma case (D: case 15). (B,
E) Latent membrane EBV protein (LMP-1) was occasionally detected in the active MS lesion (B: case 4B) and Hodgkin lymphoma (E: case 16). (C, F) Lytic
virus replication, as assessed by staining with gp350 antibody, was only occasionally detected in the active MS lesion (C: case 4B) but was pronounced in
oral hairy leukoplakia (OHL) (F: case 18). A–C: scale bar: 20 m; D–F: scale bar: 30 m.
Figure 3 Active multiple sclerosis (MS) lesions carry an interferon  (IFN)/EBV-encoded RNA
(EBER) signature
IFN cells (A) and EBER cells (B) in whitematter areas of an acuteMS lesion (case 3). IFN cells (D) and EBER cells (E)
can only occasionally be found in white matter areas of an inactive MS lesion (case 6B). CD79 B cells in acute MS lesion
(C) and inactive MS lesion (F). Scale bar: 20 m.
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nent in the parenchyma, whereas inactive MS lesions
showed only the occasional IFN or EBER cell
(figure 3, D and E). The majority of perivascular and
parenchymal EBER cells had the morphology and
distribution of B cells, which correlated with lesion
activity (figure 3, B, C, E, and F).
We conclude that EBV infection is present in ac-
tive white matter MS lesions. Most infected cells har-
bor latent virus. EBER cells were more prominent
than LMP-1 cells, only occasional cells undergoing
lytic replication.
Is cerebral expression of EBERs restricted to MS? We
next studied brains affected by a variety of other dis-
orders. EBER cells were detected in perivascular
areas in HIV-associated CNS lymphoma (figure 4B).
Stroke is another neurologic disease, where inflam-
mation appears to play an important early role in
pathogenesis.22 Interestingly, we detected EBER
cells in 2 cases of stroke (figure 4C and figure e-2, E)
but not in the white matter of healthy control brains
(figure 4D). The EBER cells were dispersedly lo-
cated all over the inflammatory area (both perivascu-
lar and in the parenchyma). Evidently, EBER cells
can be found in other inflammatory conditions such
as stroke, which raises interesting questions about
their contribution to neuroinflammation in general.
EBERs elicit IFN production in TLR3-expressing
HEK cell cultures. Finally, we tested whether EBERs
could elicit IFN production and thus contribute to
neuroinflammation in the CNS. EBERs form
double-stranded (ds) RNA-like molecules with stem-
loop structures.23 Virally encoded dsRNAs are one of
the proximal inducers of type I IFN production, and
their effects can be mimicked by treatment of unin-
fected cells with the synthetic dsRNA, poly(I):
poly(C) (polyIC).24 HEK cells, stably expressing
TLR3, were supertransfected with polyIC, which in-
duced significant IFN production (figure 5). Pro-
duction of IFN also increased significantly when
these cells were transfected instead with either
EBER1 or EBER2 expression plasmids. Thus even
latent EBV infection can trigger IFN production
observed in active MS lesions, and therefore contrib-
ute to the neuroinflammation.
DISCUSSION The MS brain shows characteristic
inflammation that targets myelin sheaths and leads to
focal destruction and demyelinated plaques in the
white matter. Analysis of white matter areas revealed
overexpression of the proinflammatory cytokine
IFN in active MS lesions. Notably, we found
EBER cells in areas of IFN overexpression. Fur-
thermore, the occasional LMP-1 and gp350 cells
were also present in EBERMS lesions. Whereas we
detected no signs of EBV infection in white matter
areas of SSPE, HSE, and control brains, EBER
cells were also present in CNS lymphoma and stroke.
We also showed that EBERs can elicit IFN produc-
tion by TLR3 HEK cells, and can thus contribute
to the inflammation in active MS lesions. Together
with the overexpression of IFN that we found there
too, these findings imply activation of innate im-
mune responses associated with the hitherto unre-
Figure 4 In situ hybridization for EBV-encoded RNA (EBER) in non–multiple
sclerosis (MS) control CNS tissue
(A) Presence of EBER cells (brown signal) in perivascular area of active MS lesion (case 3)
and (B) in HIV-associated CNS lymphoma (case 14). (C) Perivascular area of stroke case
(case 12) and in (D) another neurologic control (case 8). Scale bar: 40 m.
Figure 5 Epstein-Barr virus–encoded RNA (EBER)1 and EBER2 transfection
into TLR3-expressing human embryonic kidney (HEK)293 cells
elicits interferon  (IFN) production
Significant production of IFN upon transfection of TLR3-expressing HEK293 cells with
plasmids encoding EBER1 or EBER2 (EBER1: p  0.0064, EBER2: p  0.024, vs vector
alone) and polyIC (p0.0118). Data are also shown for cells transfectedwith empty vector
or poly IC. The graph shows mean levels of IFN production 24 hours post-transfection.
Error bars represent the SD of 3 independent experiments.
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ported EBV infection, consistent with its proposed
involvement in MS pathogenesis. Our findings sug-
gest that latent EBV infection may contribute signif-
icantly to neuroinflammation in patients with MS
and possible others, too.
Production of IFN is seen during many differ-
ent systemic virus infections, e.g., EBV,25 Sendai,26
and measles viruses.27 However, there are endoge-
nous stimuli too, as in systemic lupus erythematosus
(SLE)28 and Aicardi-Goutie`res syndrome.29 Several
CNS disorders such as encephalitis30 and neuropsy-
chiatric lupus28 have been linked to dysregulation of
IFN responses. We found HLA class II cells with
the morphology of microglia and macrophages ex-
pressed IFN in active MS lesions in line with previ-
ous study.31 The presence of plasmacytoid dendritic
cells (pDCs) was assessed with 3 pDCs markers
(BDCA-2, CD123, CD2ap); pDCs were not de-
tected in active MS lesions in contrast to previous
findings32 (figure e-1B).
Though the possible roles of viruses in the patho-
genesis of MS have been discussed for many
years,33–35 there are conflicting recent reports on EBV
infection in the MS brain.6–9 Our findings are in line
with previous reports, which describe the presence of
EBER cells in the MS lesions6 and the observation
that active EBV infection is not a characteristic fea-
ture of the MS brain.7–9 However, our study included
a novel preselection strategy and focused only on
white matter MS lesions rather than meningeal areas.
We believe that there are 2 primary reasons for the
discrepancies in previous reports: the sensitivity and
specificity of the methodology and the clinical mate-
rial used. Techniques such as PCR, albeit very sensi-
tive, are dependent on the quality of the extracted
DNA, which is generally very poor from formalin-
fixed tissues and amplification of larger fragments of
EBV (300 bp) is not consistently possible.36 In this
context, using EBER-ISH is highly favored. How-
ever, during the establishment of the EBER-ISH
methodology, we have identified that factors such as
tissue digestion, probe design, labeling of EBER
probes, amount of probe used, microwave heating
prior to overnight hybridization, and the stringency
washes posthybridization influenced its sensitivity
and specificity.10 Our probe targets EBER1 and
EBER2 in contrast to all the other studies.6–9 With
our optimized protocol, we have consistently been
able to detect as little as a few EBV-infected lympho-
cytes in entire sections.37
As we found EBER cells not only in white mat-
ter areas of these active MS lesions but also CNS
lymphoma and 2 cases of stroke, we conclude that
the presence of EBV may not be unique to the MS
brain in contrast to previous findings.6 Indeed, some
EBER cells may well be included in the inflamma-
tory infiltrate, attracted by locally produced chemo-
kines and cytokines. We did not find EBER cells in
our SSPE and HSE cases. The inflammatory infil-
trate may differ in SSPE and HSE. Alternatively
these cases may not yet be infected with EBV, as in
the teenage SSPE case.
Our data addressing a potential mechanism of ac-
tion, e.g., the role of EBERs in eliciting IFN pro-
duction, were supported by recent findings, which
showed active secretion of EBERs and binding to
extracellular TLR3 on dendritic cells, which trig-
gered type I IFN production.11 More recently, ex-
pression of EBER1 in lymphoblastoid cell lines was
found to regulate IFN6, 5, and 4 genes.38 In
addition, binding of EBERs to cytosolic “receptor”
retinoic acid inducible gene 1 (RIG-I) also induced
type-I IFN production.39,40
Future studies should include more suitable con-
trol cases as this will be crucial to understand the role
of EBV in MS. Further characterization of EBER
cells is also warranted as not all cells have the mor-
phology of B cells, which is technically extremely dif-
ficult given the few EBV-infected cells and problems
in combining immunohistochemistry with in situ
hybridization without compromising sensitivity and
specificity.
Our study indicates that EBV may be more subtle
than we anticipated as active EBV infection is not a
characteristic feature of the MS brain. Perhaps that is
not too surprising as EBV is a persistent virus with
the aim to coexist rather than eradicate the host.
Thus our study casts new light on mechanistic inter-
actions of viral RNAs and innate immune activation
in the CNS, and may highlight the propensity of
latent viral infections to contribute to neuroinflam-
mation in the CNS, not only in MS but also in other
neuroinflammatory diseases.
AUTHOR CONTRIBUTIONS
Dr. Tzartos: drafting/revising the manuscript, study concept or design,
analysis or interpretation of data, contribution of vital reagents/tools/
patients, acquisition of data. Prof. Khan: drafting/revising the manuscript,
study concept or design, analysis or interpretation of data, contribution of
vital reagents/tools/patients, acquisition of data, obtaining funding. Dr.
Vossenkamper: drafting/revising the manuscript, analysis or interpreta-
tion of data, contribution of vital reagents/tools/patients, acquisition of
data. Dr. Cruz-Sadaba: drafting/revising the manuscript, analysis or inter-
pretation of data, contribution of vital reagents/tools/patients, acquisition
of data. S. Lonardi: drafting/revising the manuscript, acquisition of data.
E. Sefia: analysis or interpretation of data, acquisition of data. Dr. Meager:
drafting/revising the manuscript, contribution of vital reagents/tools/
patients. Dr. Elia: drafting/revising the manuscript, analysis or interpreta-
tion of data, acquisition of data. Prof. Middeldorp: drafting/revising the
manuscript, analysis or interpretation of data, contribution of vital re-
agents/tools/patients, data analysis and interpretation. Prof. Clemens:
drafting/revising the manuscript, analysis or interpretation of data. Prof.
Farrell: study concept or design, analysis or interpretation of data, contri-
bution of vital reagents/tools/patients. Prof. Giovannoni: drafting/revis-
ing the manuscript, study concept or design, analysis or interpretation of
Neurology 78 January 3, 2012 21
data, study supervision, obtaining funding. Dr. Meier: drafting/revising
the manuscript, study concept or design, analysis or interpretation of data,
contribution of vital reagents/tools/patients, acquisition of data, statistical
analysis, study supervision, obtaining funding.
ACKNOWLEDGMENT
The authors thank the Thomas Willis Oxford Brain Collection for pro-
viding human tissue; Profs. Margaret Esiri, Luisa Maria Villar Guimerans,
Sir Anthony Epstein, and Dr. Josef Mautner for advice and discussion;
Prof. Nick Willcox for critical reading of the manuscript; Elisa Bonomi
for technical support; Prof. Margaret Jones for the donation of the anti-
CD79 antibody; Carolyn Sloan and Marie Hamard for tissue cutting;
and Dr. Cosimo Maggiore for help with the ethics application.
DISCLOSURE
Dr. Tzartos has a patent pending re: Methods for detecting the presence
of target molecules in a biological sample. Prof. Khan reports no disclo-
sures. Dr. Vossenkamper receives research support from the Medical Re-
search Council, UK. Dr. Cruz-Sadaba receives research support from the
Medical Research Council, UK. Dr. Lonardi and E. Sefia report no disclo-
sures. Dr. Meager serves on the editorial board of the Journal of Interferon
and Cytokine Research and receives publishing royalties for The Interferons:
Characterization and Application (Wiley-VCH Verlag GmbH & Co.
KGaA, 2006). Dr. Elia receives research support from The Wellcome
Trust. Prof. Middeldorp reports no disclosures. Prof. Clemens receives
research support from The Wellcome Trust. Prof. Farrell serves on the
editorial boards of the Journal of Virology and the Journal of General Virol-
ogy and receives research support from Leukaemia and Lymphoma Re-
search, UK. Prof. Giovannoni serves on scientific advisory boards for
Merck Serono and Biogen Idec and Vertex Pharmaceuticals; served on the
editorial board of Multiple Sclerosis; has received speaker honoraria from
Bayer Schering Pharma, Merck Serono, Biogen Idec, Pfizer Inc, Teva
Pharmaceutical Industries Ltd.–sanofi-aventis, Vertex Pharmaceuticals,
Genzyme Corporation, Ironwood, and Novartis; has served as a consul-
tant for Bayer Schering Pharma, Biogen Idec, GlaxoSmithKline, Merck
Serono, Protein Discovery Laboratories, Teva Pharmaceutical Industries
Ltd.–sanofi-aventis, UCB, Vertex Pharmaceuticals, GW Pharma, No-
vartis, and FivePrime; serves on the speakers bureau for Merck Serono;
and has received research support from Bayer Schering Pharma, Biogen
Idec, Merck Serono, Novartis, UCB, Merz Pharmaceuticals, LLC, Teva
Pharmaceutical Industries Ltd.–sanofi-aventis, GW Pharma, and Iron-
wood. Dr. Meier receives research support from British Technology
Group, ABN/MS Society, Aims2Cure, and the Roan Charitable Trust.
Received December 14, 2010. Accepted in final form June 27, 2011.
REFERENCES
1. Randall RE, Goodbourn S. Interferons and viruses: an in-
terplay between induction, signalling, antiviral responses
and virus countermeasures. J Gen Virol 2008;89:1–47.
2. Jack CS, Arbour N, Blain M, Meier UC, Prat A, Antel JP.
Th1 polarization of CD4 T cells by Toll-like receptor
3-activated human microglia. J Neuropathol Exp Neurol
2007;66:848–859.
3. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucle-
osis and risk for multiple sclerosis: a meta-analysis. Ann
Neurol 2006;59:499–503.
4. Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr
virus antibodies and risk of multiple sclerosis: a prospective
study. JAMA 2001;286:3083–3088.
5. Farrell RA, Antony D, Wall GR, et al. Humoral immune
response to EBV in multiple sclerosis is associated with
disease activity on MRI. Neurology 2009;73:32–38.
6. Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated
Epstein-Barr virus infection in the multiple sclerosis brain.
J Exp Med 2007;204:2899–2912.
7. Willis SN, Stadelmann C, Rodig SJ, et al. Epstein-Barr
virus infection is not a characteristic feature of multiple
sclerosis brain. Brain 2009;132:3318–3328.
8. Peferoen LA, Lamers F, Lodder LN, et al. Epstein Barr
virus is not a characteristic feature in the central nervous
system in established multiple sclerosis. Brain 2010;133:
e137.
9. Sargsyan SA, Shearer AJ, Ritchie AM, et al. Absence of
Epstein-Barr virus in the brain and CSF of patients with
multiple sclerosis. Neurology 2010;74:1127–1135.
10. Khan G, Coates PJ, Kangro HO, Slavin G. Epstein Barr
virus (EBV) encoded small RNAs: targets for detection by
in situ hybridisation with oligonucleotide probes. J Clin
Pathol 1992;45:616–620.
11. Iwakiri D, Zhou L, Samanta M, et al. Epstein-Barr virus
(EBV)-encoded small RNA is released from EBV-infected
cells and activates signaling from Toll-like receptor 3.
J Exp Med 2009;206:2091–2099.
12. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17
production in central nervous system-infiltrating T cells
and glial cells is associated with active disease in multiple
sclerosis. Am J Pathol 2008;172:146–155.
13. Foulis AK, Farquharson MA, Meager A. Immunoreactive
alpha-interferon in insulin-secreting beta cells in type 1
diabetes mellitus. Lancet 1987;2:1423–1427.
14. Mason DY, Cordell JL, Brown MH, et al. CD79a: a novel
marker for B-cell neoplasms in routinely processed tissue
samples. Blood 1995;86:1453–1459.
15. Middeldorp JM, Meloen RH. Epitope-mapping on the
Epstein-Barr virus major capsid protein using systematic
synthesis of overlapping oligopeptides. J Virol Methods
1988;21:147–159.
16. Vermi W, Lonardi S, Morassi M, et al. Cutaneous distri-
bution of plasmacytoid dendritic cells in lupus erythema-
tosus: selective tropism at the site of epithelial apoptotic
damage. Immunobiology 2009;214:877–886.
17. Vermi W, Fisogni S, Salogni L, et al. Spontaneous regres-
sion of highly immunogenic Molluscum contagiosum vi-
rus (MCV)-induced skin lesions is associated with
plasmacytoid dendritic cells and IFN-DC infiltration. J In-
vest Dermatol 2011;131:426–434.
18. Marafioti T, Paterson JC, Ballabio E, et al. Novel markers
of normal and neoplastic human plasmacytoid dendritic
cells. Blood 2008;111:3778–3792.
19. Khan G. Screening for Epstein-Barr virus in Hodgkin’s
lymphoma. Methods Mol Biol 2009;511:311–322.
20. Gulley ML, Glaser SL, Craig FE, et al. Guidelines for in-
terpreting EBER in situ hybridization and LMP1 immu-
nohistochemical tests for detecting Epstein-Barr virus in
Hodgkin lymphoma. Am J Clin Pathol 2002;117:259–
267.
21. Woulfe J, Hoogendoorn H, Tarnopolsky M, Munoz DG.
Monoclonal antibodies against Epstein-Barr virus cross-
react with alpha-synuclein in human brain. Neurology
2000;55:1398–1401.
22. Jin R, Yang G, Li G. Inflammatory mechanisms in isch-
emic stroke: role of inflammatory cells. J Leukoc Biol
2010;87:779–789.
23. Toczyski DP, Steitz JA. The cellular RNA-binding protein
EAP recognizes a conserved stem-loop in the Epstein-Barr
virus small RNA EBER 1. Mol Cell Biol 1993;13:703–
710.
24. Fortier ME, Kent S, Ashdown H, Poole S, Boksa P,
Luheshi GN. The viral mimic, polyinosinic:polycytidylic
22 Neurology 78 January 3, 2012
acid, induces fever in rats via an interleukin-1-dependent
mechanism. Am J Physiol Regul Integr Comp Physiol
2004;287:R759–R766.
25. Lotz M, Tsoukas CD, Fong S, Dinarello CA, Carson DA,
Vaughan JH. Release of lymphokines after Epstein Barr
virus infection in vitro: I: sources of and kinetics of pro-
duction of interferons and interleukins in normal humans.
J Immunol 1986;136:3636–3642.
26. Akerlund K, Bjork L, Fehniger T, Pohl G, Andersson J,
Andersson U. Sendai virus-induced IFN-alpha production
analysed by immunocytochemistry and computerized im-
age analysis. Scand J Immunol 1996;44:345–353.
27. Helin E, Vainionpaa R, Hyypia T, Julkunen I, Matikainen
S. Measles virus activates NF-kappa B and STAT tran-
scription factors and production of IFN-alpha/beta and
IL-6 in the human lung epithelial cell line A549. Virology
2001;290:1–10.
28. Santer DM, Yoshio T, Minota S, Moller T, Elkon KB.
Potent induction of IFN-alpha and chemokines by auto-
antibodies in the cerebrospinal fluid of patients with neu-
ropsychiatric lupus. J Immunol 2009;182:1192–1201.
29. Jepps H, Seal S, Hattingh L, Crow YJ. The neonatal form
of Aicardi-Goutieres syndrome masquerading as congeni-
tal infection. Early Hum Dev 2008;84:783–785.
30. Sas AR, Bimonte-Nelson H, Smothers CT, Woodward J,
Tyor WR. Interferon-alpha causes neuronal dysfunction in
encephalitis. J Neurosci 2009;29:3948–3955.
31. Traugott U, Lebon P. Multiple sclerosis: involvement of
interferons in lesion pathogenesis. Ann Neurol 1988;24:
243–251.
32. Lande R, Gafa V, Serafini B, et al. Plasmacytoid dendritic
cells in multiple sclerosis: intracerebral recruitment and
impaired maturation in response to interferon-beta. J Neu-
ropathol Exp Neurol 2008;67:388–401.
33. Scarisbrick IA, Rodriguez M. Hit-hit and hit-run: viruses
in the playing field of multiple sclerosis. Curr Neurol Neu-
rosci Rep 2003;3:265–271.
34. Meinl E. Concepts of viral pathogenesis of multiple sclero-
sis. Curr Opin Neurol 1999;12:303–307.
35. Ascherio A, Munch M. Epstein-Barr virus and multiple
sclerosis. Epidemiology 2000;11:220–224.
36. Coates PJ, d’Ardenne AJ, Khan G, Kangro HO, Slavin G.
Simplified procedures for applying the polymerase chain
reaction to routinely fixed paraffin wax sections. J Clin
Pathol 1991;44:115–118.
37. Khan G, Coates PJ, Gupta RK, Kangro HO, Slavin G.
Presence of Epstein-Barr virus in Hodgkin’s disease is not
exclusive to Reed-Sternberg cells. Am J Pathol 1992;140:
757–762.
38. Gregorovic G, Bosshard R, Karstegl CE, et al. Cellular gene
expression that correlates with EBER expression in Epstein-
Barr virus-infected lymphoblastoid cell lines. J Virol 2011;85:
3535–3545.
39. Samanta M, Iwakiri D, Kanda T, Imaizumi T, Takada K.
EB virus-encoded RNAs are recognized by RIG-I and acti-
vate signaling to induce type I IFN. Embo J 2006;25:
4207–4214.
40. Pichlmair A, Schulz O, Tan CP, et al. RIG-I-mediated
antiviral responses to single-stranded RNA bearing 5	-
phosphates. Science 2006;314:997–1001.
Neurologists Needed to Volunteer in Haiti
The AAN is working with Operation Blessing International (OBI) to promote opportunities for
neurologists to aid the victims of the January 2010 earthquake in Haiti. For one to two weeks,
physician volunteers will care for patients with a variety of needs, and offer neurologic care when
necessary. To learn more about the work of OBI and this unique volunteer program, visit
www.ob.org/haitiprojects/volunteer.asp.
Get the Latest Drug Recalls and Warnings. Give the
Best Patient Care
The American Academy of Neurology and the Health Care Notification Network have teamed up
to offer AAN members a FREE service that delivers timely neurology-specific FDA-mandated
patient safety drug alerts directly to your e-mail inbox.
Don’t miss this opportunity to provide the best—and safest—possible care for your patients:
visit www.aan.com/view/FDAalerts.
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